{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:31:46Z","timestamp":1787841106981,"version":"build-2784847793"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptor T-cell (CAR T-cell) therapy represents an innovative and transformative therapy for patients with relapsed and\/or refractory (R\/R) hematological malignancies. CAR T-cell therapy was first approved in R\/R diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia, today the use of CAR T-cell therapy has expanded to multiple myeloma and other lymphoma subtypes such as follicular and mantle cell lymphoma. It is also being explored in earlier lines of therapy in DLBCL. CAR T-cell therapy is associated with a unique toxicity profile and development of cytopenias post CAR T-cell therapy has been reported in all pivotal clinical trials and is now considered a related side effect. Here, we provide an in-depth evaluation of etiologies, consequences, and current management strategies for cytopenias following CAR T-cell therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.56875\/2589-0646.1047","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T05:28:27Z","timestamp":1671686907000},"page":"122-130","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Understanding the Etiology of Pancytopenias in the CAR T-Cell Therapy Setting"],"prefix":"10.4103","volume":"15","author":[{"given":"Farah","family":"Yassine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Ghabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20241211","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-8-20241211","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"R3-8-20241211","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenle- cleucel in patients with relapsed or refractory aggressive B- cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"R4-8-20241211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"R5-8-20241211","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-8-20241211","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-8-20241211","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"R8-8-20241211","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"R9-8-20241211","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"R10-8-20241211","doi-asserted-by":"crossref","first-page":"702644","DOI":"10.3389\/fonc.2021.702644","article-title":"New- onset severe cytopenia after CAR-T cell therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"R11-8-20241211","doi-asserted-by":"crossref","first-page":"8901","DOI":"10.2147\/CMAR.S321202","article-title":"Cytopenias after CD19 chimeric antigen receptor T-cells (CAR-T) therapy for diffuse large B-cell lymphomas or transformed follicular lymphoma: a single institution experience","volume":"13","author":"Schaefer","year":"2021","journal-title":"Cancer Manag Res"},{"key":"R12-8-20241211","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"R13-8-20241211","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am J Hematol"},{"key":"R14-8-20241211","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"R15-8-20241211","doi-asserted-by":"crossref","first-page":"963689720919434","DOI":"10.1177\/0963689720919434","article-title":"Factors associated with costs in chimeric antigen receptor T- cell therapy for patients with relapsed\/refractory B-cell malignancies","volume":"29","author":"Zhu","year":"2020","journal-title":"Cell Transplant"},{"key":"R16-8-20241211","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jha2.350","article-title":"CAR-T-OPENIA: chimeric antigen receptor T-cell therapy-associated cytopenias","volume":"3","author":"Taneja","year":"2022","journal-title":"EJHaem"},{"key":"R17-8-20241211","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"R18-8-20241211","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R19-8-20241211","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","article-title":"Diagnosis and management of secondary HLH\/MAS following hsct and CAR-T cell therapy in adults; A review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party (ADWP) and transplant complications working party (TCWP)","volume":"11","author":"Sandler","year":"2020","journal-title":"Front Immunol"},{"key":"R20-8-20241211","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"key":"R21-8-20241211","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axi- cabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"R22-8-20241211","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"key":"R23-8-20241211","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-141833","article-title":"Identification of predictive markers of severe and prolonged neutropenia after CD19-specific CAR T-cell treatment in patients with relapsed\/refractory B-cell malignancies","volume":"136","author":"Rejeski","year":"2020","journal-title":"Blood"},{"key":"R24-8-20241211","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"R25-8-20241211","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19- targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R26-8-20241211","first-page":"333","article-title":"Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome","volume":"19","author":"Guo","year":"2021","journal-title":"Cancer Biol Med"},{"key":"R27-8-20241211","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"key":"R28-8-20241211","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"R29-8-20241211","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"key":"R30-8-20241211","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv"},{"key":"R31-8-20241211","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"R32-8-20241211","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R33-8-20241211","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","article-title":"B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis","volume":"106","author":"Dunleavy","year":"2005","journal-title":"Blood"},{"key":"R34-8-20241211","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"R35-8-20241211","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"R36-8-20241211","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/sci-2021-008","article-title":"Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting","volume":"8","author":"Thakkar","year":"2021","journal-title":"Stem Cell Invest"},{"key":"R37-8-20241211","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","article-title":"Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy","volume":"5","author":"Johnsrud","year":"2021","journal-title":"Blood Adv"},{"key":"R38-8-20241211","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","article-title":"G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma","volume":"55","author":"Galli","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R39-8-20241211","doi-asserted-by":"crossref","first-page":"E399","DOI":"10.1002\/ajh.26313","article-title":"The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy","volume":"96","author":"Barreto","year":"2021","journal-title":"Am J Hematol"},{"key":"R40-8-20241211","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"R41-8-20241211","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"R43-8-20241211","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1182\/blood-2021-150975","article-title":"Dynamics and management of CAR-T cells associated cytopenias: a single-center experience","volume":"138","author":"Mart\u00edn-Rojas","year":"2021","journal-title":"Blood"},{"key":"R44-8-20241211","doi-asserted-by":"crossref","first-page":"798352","DOI":"10.3389\/fonc.2021.798352","article-title":"Case report: sirolimus alleviates persistent cytopenia after CD19 CAR-T-cell therapy","volume":"11","author":"Xing","year":"2021","journal-title":"Front Oncol"},{"key":"R45-8-20241211","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1097\/HS9.0000000000000545","article-title":"Hematologic rescue of CAR T-cell- mediated prolonged pancytopenia using autologous peripheral blood hematopoietic stem cells in a lymphoma patient","volume":"5","author":"G\u00f6del","year":"2021","journal-title":"Hemasphere"},{"key":"R46-8-20241211","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41409-019-0674-2","article-title":"Autologous hematopoietic stem cell infusion for sustained myelosup- pression after BCMA-CAR-T therapy in patient with relapsed myeloma","volume":"55","author":"Lin","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R47-8-20241211","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"R49-8-20241211","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/bjh.17737","article-title":"Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation","volume":"195","author":"Gabelli","year":"2021","journal-title":"Br J Haematol"},{"key":"R50-8-20241211","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"R51-8-20241211","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"R52-8-20241211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2021-147913","article-title":"Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study","volume":"138","author":"Kamdar","year":"2021","journal-title":"Blood"},{"key":"R53-8-20241211","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"R54-8-20241211","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"key":"R55-8-20241211","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"key":"R56-8-20241211","doi-asserted-by":"crossref","first-page":"e28092","DOI":"10.1002\/pbc.28092","article-title":"Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients","volume":"67","author":"Arnold","year":"2020","journal-title":"Pediatr Blood Cancer"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:41:06Z","timestamp":1787838066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1047"}},"subtitle":["What We Know and What We Don't?"],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.56875\/2589-0646.1047","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}